Potential of GLP-1 Weight-Loss Drugs in Cancer Progression Control

Glucagon-like peptide-1 (GLP-1) weight-loss drugs might offer benefits in slowing cancer spread, according to recent research. This study, conducted by Cleveland Clinic, suggests that these medications could reduce the spread of certain obesity-related cancers, including lung, breast, colorectal, and liver cancers. The findings are set to be presented at the 2026 ASCO Annual Meeting in Chicago.

Study Details

The real-world analysis included 12,112 patients with various obesity-related cancers, ranging from stage 1 to stage 3. These cancers include breast adenocarcinoma, prostate adenocarcinoma, non-small cell lung cancer (NSCLC), colorectal adenocarcinoma, hepatocellular carcinoma (liver cancer), renal cell carcinoma, and pancreatic adenocarcinoma.

Participants were divided into two groups, with one receiving GLP-1 medications like semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, or pramlintide after their cancer diagnosis. The other group started a different class of diabetes medication, DPP-4 inhibitors (gliptins).

Results and Findings

The study found that patients using GLP-1 drugs exhibited significantly lower progression to stage 4 disease in four cancer types. The risk reduction was notable for non-small cell lung cancer (50%), breast cancer (43%), colorectal cancer (31%), and liver cancer (38%). Lead researcher Mark David Orland, MD, emphasized the importance of these findings, stating it provides early evidence for the potential of GLP-1 drugs in reducing cancer progression.

Additionally, improved survival outcomes were linked to tumors with higher levels of GLP-1 receptors, proteins assisting cells in responding to GLP-1 hormones and drugs. Results showed that patients with these tumors were about one-third less likely to die during the study period.

Further Investigation Required

The study suggests an influence of GLP-1 pathways on cancer growth and spread. However, more studies are necessary to fully understand the mechanisms behind this effect. Although the study found differences in the spread of prostate, pancreatic, and kidney cancers among those taking GLP-1 drugs, these were not statistically significant.

The research, observational and retrospective in nature, highlights potential limitations. It does not prove a direct prevention of cancer progression by GLP-1 drugs. Additional factors like health conditions, weight loss, and metabolic improvements might have influenced outcomes. Future randomized clinical trials are crucial to validate these preliminary observations and define how GLP-1s may control cancer progression.